

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 62648

Title: Molecular-targeted therapy toward precision medicine for gastrointestinal cancer:
Current progress and challenges

Reviewer's code: 03093768

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Doctor, Surgeon, Surgical Oncologist

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2021-01-14

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2021-01-14 11:34

Reviewer performed review: 2021-01-17 10:42

Review time: 2 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

The content of the review is very comprehensive, which summarizes the advancement of precision medicine in GI cancer. The first part named "targeting the RAS / Raf / MEK pathway" seems not proper, why not named it "targeting EGFR"? Maybe this title is more consistent with the following figures and tables. I believe it is necessary to properly introduce the relationship between RAS / Raf / MEK pathway and EGFR. It seems that the writing style of this part is not consistent with that of the following parts.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 62648

Title: Molecular-targeted therapy toward precision medicine for gastrointestinal cancer:
Current progress and challenges

Reviewer's code: 03080579

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2021-01-14

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2021-01-16 01:19

Reviewer performed review: 2021-01-28 04:19

Review time: 12 Days and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The manuscript clarifies the current evidence for targeted therapies in GI cancer by evaluating the latest data regarding anti-EGFR, HER2, VEGF, PI3K/AKT, TGF- β , MET, WNT, PARP and immunotherapies. And Targeting these molecules will improve the outcomes of patients with GI cancer. The review concept is clear. And the manuscript is well and concisely written. However, English editing is required.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 62648

Title: Molecular-targeted therapy toward precision medicine for gastrointestinal cancer:
Current progress and challenges

Reviewer's code: 03093768

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Doctor, Surgeon, Surgical Oncologist

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2021-01-14

Reviewer chosen by: Le Zhang

Reviewer accepted review: 2021-03-09 10:32

Reviewer performed review: 2021-03-09 12:01

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Thank you for your work in revising your manuscript. I think this manuscript is good enough to be accepted for publication.